Authors
Latest:
Importance of Patient-Reported Outcomes in the GRIFFIN StudyRebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.
Latest:
Analyzing the ESPAC-5F Trial in Borderline Resectable Pancreatic CancerShubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.
Latest:
Long-Term HERIZON-BTC-01 Data Shows Zanidatamab’s Potential in HER2+ BTCShubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.
Latest:
How Do These Data Apply to Community Oncologists?Explanation of how these data apply to community oncologists.
Latest:
Sequencing Therapies in the First and Second Line for Patients With HCCLipika Goyal, MD, discusses first-line options for patients with patients with hepatocellular carcinoma.
Latest:
Advances in CAR T-Cell Therapy in Hematologic MalignanciesKruti Patel, DO, reviews the advancements, landmark trials, and challenges with CAR T-cell therapy for Cancer Immunotherapy Month.
Latest:
Key Clinical Insights for the Management of Newly Diagnosed Multiple MyelomaPractical insights for the management of patients with NDMM.
Latest:
Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCLMatthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Zolbetuximab Plus mFOLFOX for CLDN18.2+/HER2- Advanced Gastric/GEJ CancersSamuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study.
Latest:
Recommendations for Diagnosing and Treating Rare Histiocytic NeoplasmsRonald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.
Latest:
Olszewski Recaps Results of Mosunetuzumab in Elderly/Unfit DLBCLAdam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma.
Latest:
Emerging Therapies Are Explored in Low- and High-Risk MDSFor patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.
Latest:
The Promise of IL-21 Engineered NK Cells in Glioblastoma TreatmentMayra Shanley, PhD, discussed background and future directions for evaluating IL-21 natural killer cells for the treatment of glioblastoma.
Latest:
Thomas Discusses Non-Melanoma Skin CancersValencia D. Thomas, MD, MHCM, discusses the current landscape for patients with non-melanoma skin cancers.
Latest:
ADRIATIC Study Highlights Survival Gains With Durvalumab in LS-SCLCAakash Desai, MD, MPH, discusses the ADRIATIC study in limited-stage small cell lung cancer.
Latest:
Bispecific T-Cell Engagers Improve Immune Response in Multiple MyelomaThomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.
Latest:
Technology Drives Biomarker Testing Rates in Precision OncologyThe knowledge gained from biomarker testing can help develop cancer prevention, diagnosis, and treatment strategies that specifically target a person’s cancer subtype.
Latest:
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantCareful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Latest:
Key Findings From BOND-003: Cretostimogene Grenadenorepvec in NMIBCMark D. Tyson, II, MD, MPH, discusses the safety and efficacy findings from the BOND-003 trial of cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Latest:
Bahary on the Response to Chemotherapy Drug Shortages at AHNNathan Bahary, MD, PhD, discusses how Allegheny Health Network has been able to combat the recent chemotherapy drug shortages seen nationwide.
Latest:
Molecular Subtyping Leads to New Targeted Trials in Endometrial CancerRuchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.
Latest:
Lu 177 Vipivotide Tetraxetan Approved for PSMA-Positive mCRPCRichard L. Wahl, MD, discusses the approval of lutetium Lu 177 vipivotide tetraxetan for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Latest:
Palliative Care Plays Important Role in Advanced CancersKavitha Ramchandran, MD, discusses the role of palliative care for patients with cancer, particularly those with advanced stage disease.
Latest:
Ongoing Trials Investigate Amivantamab Combinations for EGFR+ NSCLCMelina E. Marmarelis, MD, reports the study design of the Chrysalis-2 trial and ongoing trials researching the combination of amivantamab and lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer.
Latest:
The Future of Breast Cancer Care: Blackwood on Personalized ApproachesIn this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
Latest:
Bemcentinib/Pembrolizumab Shows Clinical Activity, Tolerability in Advanced NSCLCPatients with checkpoint inhibitor-naïve and refractory composite AXL-positive non—small cell lung cancer, responded to treatmen with the first-in-class oral kinase inhibitor bemcentinib in combination with pembrolizumab, and the compound was well-tolerated, according to updated results from the phase 2 BGBC008 clinical trial.
Latest:
Evaluating the Feasibility of Liso-cel Administration in the Outpatient SettingCarlos R. Bachier, MD, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel demonstrated the feasibility of outpatient administration of chimeric antigen receptor T-cell therapy.
Latest:
cfDNA & CTCs for Early Detection, Treatment Monitoring, and Personalized MedicineThe latest research on circulating tumor DNA and circulating tumor cells isolated through liquid biopsies is revolutionizing cancer care by enabling early detection, treatment monitoring, and personalized medicine strategies.
Latest:
The Importance of Identifying Genetic Alterations in Thyroid CancerLova Sun, MD, MCSE, assistant professor at the Hospital of the University of Pennsylvania, discusses the important of next-generation sequencing for patients with thyroid cancer.
